Is ELDN or IMA more profitable?

ImageneBio's return on equity of -38.99% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -149.63% -50.84% ImageneBio N/A -38.99% -34.84%

Does the media favor ELDN or IMA?

In the previous week, ImageneBio had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 2 mentions for ImageneBio and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.88 beat ImageneBio's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, IMA or ALEC?

ImageneBio has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImageneBio $800K 65.26 -$45.35M -$4.58 N/A Alector $21.05M 9.60 -$142.93M -$1.10 N/A

Is IMA or ALEC more profitable?

ImageneBio has a net margin of 0.00% compared to Alector's net margin of -850.13%. ImageneBio's return on equity of -38.99% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Alector -850.13% -531.03% -44.00%

Does the media refer more to IMA or ALEC?

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Alector's average media sentiment score of 0.67 beat ImageneBio's score of 0.00 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMA or PYXS more profitable?

ImageneBio's return on equity of -38.99% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Pyxis Oncology N/A -215.23% -112.19%

Does the media refer more to IMA or PYXS?

In the previous week, Pyxis Oncology had 9 more articles in the media than ImageneBio. MarketBeat recorded 11 mentions for Pyxis Oncology and 2 mentions for ImageneBio. Pyxis Oncology's average media sentiment score of 0.11 beat ImageneBio's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pyxis Oncology 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer IMA or ORMP?

ImageneBio presently has a consensus price target of $29.00, suggesting a potential upside of 530.43%. Given ImageneBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImageneBio is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is IMA or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% Oramed Pharmaceuticals N/A -5.17% -4.54%

Does the media favor IMA or ORMP?

In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than ImageneBio. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 2 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.00 equaled Oramed Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oramed Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ALXO or IMA more profitable?

ImageneBio's return on equity of -38.99% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -90.30% -67.28% ImageneBio N/A -38.99% -34.84%

Does the media prefer ALXO or IMA?

In the previous week, ALX Oncology had 3 more articles in the media than ImageneBio. MarketBeat recorded 5 mentions for ALX Oncology and 2 mentions for ImageneBio. ALX Oncology's average media sentiment score of 0.73 beat ImageneBio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ImageneBio (IMA) Competitors

$4.60 +0.02 (+0.44%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$4.61 +0.01 (+0.22%)

As of 10/2/2026 04:32 PM Eastern

Compare

IMA vs. ELDN, ALEC, PYXS, ORMP, and ALXO

Should you buy ImageneBio stock or one of its competitors? ImageneBio's main competitors and comparable companies include Eledon Pharmaceuticals (ELDN), Alector (ALEC), Pyxis Oncology (PYXS), Oramed Pharmaceuticals (ORMP), and ALX Oncology (ALXO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ImageneBio compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Eledon Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, ImageneBio had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 2 mentions for ImageneBio and 1 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.88 beat ImageneBio's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 301.61%. ImageneBio has a consensus price target of $29.00, indicating a potential upside of 530.43%. Given ImageneBio's higher probable upside, analysts plainly believe ImageneBio is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

ImageneBio's return on equity of -38.99% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
ImageneBio	N/A	-38.99%	-34.84%

ImageneBio has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
ImageneBio	$800K	65.26	-$45.35M	-$4.58	N/A

Summary

ImageneBio beats Eledon Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does ImageneBio compare to Alector?

ImageneBio (NASDAQ:IMA) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

ImageneBio has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Alector has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Alector's average media sentiment score of 0.67 beat ImageneBio's score of 0.00 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio currently has a consensus target price of $29.00, suggesting a potential upside of 530.43%. Alector has a consensus target price of $3.63, suggesting a potential upside of 100.28%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts plainly believe ImageneBio is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

ImageneBio has a net margin of 0.00% compared to Alector's net margin of -850.13%. ImageneBio's return on equity of -38.99% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Alector	-850.13%	-531.03%	-44.00%

ImageneBio has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	65.26	-$45.35M	-$4.58	N/A
Alector	$21.05M	9.60	-$142.93M	-$1.10	N/A

Summary

ImageneBio beats Alector on 10 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Pyxis Oncology?

ImageneBio (NASDAQ:IMA) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

ImageneBio has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

ImageneBio has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	65.26	-$45.35M	-$4.58	N/A
Pyxis Oncology	$13.86M	12.88	-$79.62M	-$1.41	N/A

In the previous week, Pyxis Oncology had 9 more articles in the media than ImageneBio. MarketBeat recorded 11 mentions for Pyxis Oncology and 2 mentions for ImageneBio. Pyxis Oncology's average media sentiment score of 0.11 beat ImageneBio's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pyxis Oncology	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ImageneBio's return on equity of -38.99% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Pyxis Oncology	N/A	-215.23%	-112.19%

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImageneBio currently has a consensus target price of $29.00, suggesting a potential upside of 530.43%. Pyxis Oncology has a consensus target price of $8.75, suggesting a potential upside of 308.88%. Given ImageneBio's higher probable upside, research analysts plainly believe ImageneBio is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

ImageneBio and Pyxis Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Oramed Pharmaceuticals?

ImageneBio (NASDAQ:IMA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Oramed Pharmaceuticals had 2 more articles in the media than ImageneBio. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 2 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.00 equaled Oramed Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oramed Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by company insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImageneBio presently has a consensus price target of $29.00, suggesting a potential upside of 530.43%. Given ImageneBio's stronger consensus rating and higher probable upside, research analysts clearly believe ImageneBio is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has lower revenue, but higher earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	65.26	-$45.35M	-$4.58	N/A
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$4.12	1.09

Oramed Pharmaceuticals' return on equity of -5.17% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

ImageneBio has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Summary

Oramed Pharmaceuticals beats ImageneBio on 8 of the 14 factors compared between the two stocks.

How does ImageneBio compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

In the previous week, ALX Oncology had 3 more articles in the media than ImageneBio. MarketBeat recorded 5 mentions for ALX Oncology and 2 mentions for ImageneBio. ALX Oncology's average media sentiment score of 0.73 beat ImageneBio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ALX Oncology has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

ImageneBio's return on equity of -38.99% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
ImageneBio	N/A	-38.99%	-34.84%

ALX Oncology presently has a consensus target price of $4.60, suggesting a potential upside of 277.05%. ImageneBio has a consensus target price of $29.00, suggesting a potential upside of 530.43%. Given ImageneBio's higher possible upside, analysts clearly believe ImageneBio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by company insiders. Comparatively, 2.2% of ImageneBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ImageneBio has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
ImageneBio	$800K	65.26	-$45.35M	-$4.58	N/A

Summary

ImageneBio beats ALX Oncology on 8 of the 15 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMA vs. The Competition

Export

Metric	ImageneBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$52.22M	$3.87B	$7.14B	$13.18B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-1.00	13.13	275.97	26.04
Price / Sales	N/A	1,416.16	669.23	109.59
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	0.39	16.63	10.93	6.31
Net Income	-$45.35M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-2.54%	-2.99%	-2.00%	-1.66%
1 Month Performance	-5.93%	-10.60%	-6.15%	-4.50%
1 Year Performance	-46.51%	19.44%	7.44%	2.06%

ImageneBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMA ImageneBio	2.6565 of 5 stars	$4.60 +0.4%	$29.00 +530.4%	-46.8%	$52.22M	N/A	N/A	18	News Coverage Gap Up
ELDN Eledon Pharmaceuticals	1.9176 of 5 stars	$2.53 +1.2%	$10.00 +295.3%	-9.8%	$205.59M	N/A	N/A	33
ALEC Alector	2.7984 of 5 stars	$1.84 -1.6%	$3.63 +97.0%	-42.7%	$205.45M	$13.86M	N/A	103	News Coverage
PYXS Pyxis Oncology	2.6929 of 5 stars	$2.33 -19.7%	$8.75 +275.5%	-4.9%	$194.34M	$11.04M	N/A	56	High Trading Volume
ORMP Oramed Pharmaceuticals	1.6809 of 5 stars	$4.67 -0.5%	N/A	+78.9%	$194.05M	N/A	1.13	13	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMA) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImageneBio (IMA) Competitors

IMA vs. ELDN, ALEC, PYXS, ORMP, and ALXO

How does ImageneBio compare to Eledon Pharmaceuticals?

Summary

How does ImageneBio compare to Alector?

Summary

How does ImageneBio compare to Pyxis Oncology?

Summary

How does ImageneBio compare to Oramed Pharmaceuticals?

Summary

How does ImageneBio compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImageneBio (IMA) Competitors

IMA vs. ELDN, ALEC, PYXS, ORMP, and ALXO

How does ImageneBio compare to Eledon Pharmaceuticals?

Which has more volatility and risk, ELDN or IMA?

Do institutionals and insiders hold more shares of ELDN or IMA?

Does the media favor ELDN or IMA?

Do analysts prefer ELDN or IMA?

Is ELDN or IMA more profitable?

Which has better earnings & valuation, ELDN or IMA?

Summary

How does ImageneBio compare to Alector?

Which has more volatility & risk, IMA or ALEC?

Do institutionals and insiders have more ownership in IMA or ALEC?

Does the media refer more to IMA or ALEC?

Do analysts recommend IMA or ALEC?

Is IMA or ALEC more profitable?

Which has better valuation and earnings, IMA or ALEC?

Summary

How does ImageneBio compare to Pyxis Oncology?

Which has more volatility & risk, IMA or PYXS?

Which has preferable valuation and earnings, IMA or PYXS?

Does the media refer more to IMA or PYXS?

Is IMA or PYXS more profitable?

Do insiders & institutionals have more ownership in IMA or PYXS?

Do analysts rate IMA or PYXS?

Summary

How does ImageneBio compare to Oramed Pharmaceuticals?

Does the media favor IMA or ORMP?

Do insiders and institutionals have more ownership in IMA or ORMP?

Do analysts prefer IMA or ORMP?

Which has preferable earnings and valuation, IMA or ORMP?

Is IMA or ORMP more profitable?

Which has more volatility & risk, IMA or ORMP?

Summary

How does ImageneBio compare to ALX Oncology?

Does the media prefer ALXO or IMA?

Which has more risk and volatility, ALXO or IMA?

Is ALXO or IMA more profitable?

Do analysts prefer ALXO or IMA?

Do institutionals & insiders have more ownership in ALXO or IMA?

Which has higher earnings & valuation, ALXO or IMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools